SCHEMBL6472891

SCHEMBL6472891

COc1ccc(-c2nc(-c3cc(C(=O)O)c(C)n3CCN3CCOCC3)cs2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 3/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 2/20 0.46
MAPT P10636 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 1/20 0.46
MMP2 P08253 1/20 0.46
MMP8 P22894 1/20 0.46
MMP12 P39900 1/20 0.46
MMP13 P45452 1/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 1/20 0.46
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
CDC25A P30304 1/20 0.45
CDC25B P30305 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473241 0.87 ATP4A (0.50) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5047805 0.86 GAA (0.53) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5044535 0.85 ALDH1A1 (0.53) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5039541 0.84 KDM4E (0.52) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5044308 0.84 ALDH1A1 (0.54) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL6879680 0.84 KDM4E (0.51) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5045711 0.83 KDM4E (0.55) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL6881143 0.83 KDM4E (0.50) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL6877086 0.82 ALDH1A1 (0.47) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL6879060 0.82 KDM4E (0.53) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885KDM4E 2916/4885NPC1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.